Eliem Therapeutics, Inc. is a biotechnology company that focuses on developing novel therapies for neuronal excitability disorders. These disorders are characterized by an imbalance in the way neurons communicate with each other, which can lead to a variety of symptoms, including psychiatric disorders, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. Eliem's goal is to restore homeostasis by developing a pipeline of clinically differentiated product candidates that focus on validated mechanisms of action with broad therapeutic potential. The company's experience, energy, and passion for improving patients' quality of life fuels its efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.